ロード中...
Emerging targeted therapies for plaque psoriasis – impact of ixekizumab
BACKGROUND: Recent studies into the pathogenesis of psoriasis have identified the importance of interleukin 17 (IL-17) in disease activity and have thus provided a new target for biologic therapy. Ixekizumab, the most recent US Food and Drug Administration (FDA)-approved anti-IL-17 biologic agent, a...
保存先:
| 出版年: | Clin Cosmet Investig Dermatol |
|---|---|
| 主要な著者: | , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Dove Medical Press
2017
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5409192/ https://ncbi.nlm.nih.gov/pubmed/28461763 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CCID.S111007 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|